Tanshinone IIA alleviates atherosclerosis in LDLR−/− mice by regulating efferocytosis of macrophages
Background: Tanshinone IIA (TIIA) is the major lipid-soluble active ingredient of the traditional Chinese medicine Salvia miltiorrhiza , which slows down atherosclerosis (AS). However, it remains unclear whether TIIA has the potential to enhance macrophage efferocytosis and thereby improve atheroscl...
Gespeichert in:
Veröffentlicht in: | Frontiers in pharmacology 2023-10, Vol.14, p.1233709-1233709 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Tanshinone IIA (TIIA) is the major lipid-soluble active ingredient of the traditional Chinese medicine
Salvia miltiorrhiza
, which slows down atherosclerosis (AS). However, it remains unclear whether TIIA has the potential to enhance macrophage efferocytosis and thereby improve atherosclerosis.
Objective:
The focus of this examination was to determine if TIIA could reduce lipid accumulation and treat AS by enhancing efferocytosis.
Methods:
Firstly, we conducted
in vivo
experiments using LDLR knockout (LDLR
−/−
) mice for a period of 24 weeks, using histopathological staining, immunofluorescence and Western blot experiments to validate from the efficacy and mechanism parts, respectively; in addition, we utilized cells to validate our study again
in vitro
. The specific experimental design scheme is as follows:
In vivo
, Western diet-fed LDLR
−/−
mice for 12 weeks were constructed as an AS model, and normal diet-fed LDLR
−/−
mice were taken as a blank control group. The TIIA group and positive control group (atorvastatin, ATO) were intervened for 12 weeks by intraperitoneal injection (15 mg/kg/d) and gavage (1.3 mg/kg/d), respectively.
In vitro
, RAW264.7 cells were cultured with ox-LDL (50 ug/mL) or ox-LDL (50 ug/mL) + TIIA (20 uM/L or 40 uM/L). Pathological changes in aortic plaques and foam cell formation in RAW264.7 cells were evaluated using Masson and Oil Red O staining, respectively. Biochemical methods were used to detect lipid levels in mice. The immunofluorescence assay was performed to detect apoptotic cells and efferocytosis-related signal expression at the plaques. RT-qPCR and Western blot were carried out to observe the trend change of efferocytosis-related molecules in both mouse aorta and RAW264.7 cells. We also used the neutral red assay to assess RAW264.7 cells’ phagocytic capacity.
Results:
Compared with the model group, TIIA decreased serum TC, TG, and LDL-C levels (
p
< 0.01), reduced the relative lumen area of murine aortic lipid-rich plaques (
p
< 0.01), enhanced the stability of murine aortic plaques (
p
< 0.01), reduced ox-LDL-induced lipid build-up in RAW264.7 cells (
p
< 0.01), and upregulated efferocytosis-related molecules expression and enhance the efferocytosis rate of ox-LDL-induced RAW264.7 cells.
Conclusion:
TIIA might reduce lipid accumulation by enhancing the efferocytosis of macrophages and thus treat AS. |
---|---|
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2023.1233709 |